Application of nitrofurantoin in the preparation of anti-rheumatoid arthritis drugs

Nitrofurantoin is used to treat rheumatoid arthritis by inhibiting synovial cell proliferation and bone loss, reducing the expression of inflammatory factors, providing a new treatment approach, overcoming the shortcomings of existing drugs, and significantly improving symptoms.

CN117643588BActive Publication Date: 2024-11-15张仁帅
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311506331.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-13
Publication Date
2024-11-15
Estimated Expiration
2043-11-13

AI Technical Summary

Technical Problem

Existing drugs for the treatment of rheumatoid arthritis have poor response and toxic side effects, which limit their long-term clinical use, and there is a lack of effective new treatments.

Method used

Nitrofurantoin is used as an antibacterial drug in the treatment of rheumatoid arthritis by inhibiting the proliferation of synovial lining cells, inhibiting osteoporosis and bone loss, reducing the expression of inflammatory factors, and promoting the expression of anti-inflammatory cytokines.

Benefits of technology

It significantly improves rheumatoid arthritis symptoms, inhibits synovial lining cell proliferation, reduces osteoporosis and bone loss, decreases the expression of inflammatory factors, and promotes the expression of anti-inflammatory factors, providing a new treatment pathway.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117643588B_ABST
    Figure CN117643588B_ABST
Patent Text Reader

Abstract

The present invention provides the application of nitrofurantoin in the preparation of anti-rheumatoid arthritis drugs, belonging to the field of pharmaceutical chemistry. The typical feature of rheumatoid arthritis is the proliferation of synovial lining cells, and nitrofurantoin significantly reduces the proliferation of synovial lining cells. In addition, nitrofurantoin can also significantly inhibit osteoporosis and bone loss caused by rheumatoid arthritis, and significantly reduce the expression of inflammatory factors (IL-1β, IL-6, IL-17, IL-23), while promoting the expression of anti-inflammatory cytokines (IL-10). The present invention applies nitrofurantoin, which was originally an antibacterial drug, to the treatment of rheumatoid arthritis, enriches the types of medication for rheumatoid arthritis, and is expected to provide a new path for the treatment of rheumatoid arthritis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical chemistry, and particularly relates to the application of nitrofurantoin in the preparation of anti-rheumatoid arthritis drugs. Background Art

[0002] Inflammation is a defensive response process of living tissues with vascular systems to damaging factors, and it is closely related to a variety of diseases. Research on inflammation and related phenomena (including the establishment of inflammation models, the discovery of inflammatory response factors, the relationship between response factors and drug action mechanisms, and inflammation and other diseases) has important guiding significance for drug development, early diagnosis of cancer, research on many physiological processes, and cancer treatment.

[0003] Rheumatoid arthritis is a relatively common inflammatory disease and a type of autoimmune disease. The incidence of this type of disease in the population is about 1%, with at least 30 million patients worldwide, mainly affecting women. It increases the risk of heart disease, lymphoma, diabetes, stroke and lung disease, and may shorten the patient's life expectancy by 10 to 15 years. At present, the pathogenesis of rheumatoid arthritis has not yet been clarified, but many breakthrough discoveries in related fields about new cells, molecules and pathways have been reported in top international academic journals, and the market size of rheumatoid arthritis has also shown significant growth. At present, drugs used for rheumatoid arthritis are mainly divided into non-steroidal anti-inflammatory drugs, anti-rheumatic drugs that improve the condition, including targeted drugs, biological agents, etc. For example, drugs that target inhibition of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and non-receptor tyrosine kinase (JAK) have shown effective clinical effects. However, these drugs usually have low response effects, are prone to cause toxic side effects such as viral infections and malignant tumors, and are limited in long-term clinical use. Therefore, the development of new drugs for the treatment of rheumatoid arthritis is of great scientific and practical significance.

[0004] Nitrofurantoin is an antibacterial drug with a broad-spectrum antibacterial activity. It can be used clinically for urinary tract infections caused by sensitive bacteria. Its clinical effectiveness and safety have been clinically confirmed. At present, there are no reports on the use of nitrofurantoin for the treatment of rheumatoid arthritis. Summary of the invention

[0005] The present invention provides the use of nitrofurantoin in the preparation of an anti-rheumatoid arthritis drug. The use of nitrofurantoin, which was originally an antibacterial drug, in the treatment of rheumatoid arthritis enriches the types of drugs for the treatment of rheumatoid arthritis and is expected to provide a new path for the treatment of rheumatoid arthritis.

[0006] The present invention is achieved through the following technical solutions:

[0007] The invention provides application of nitrofurantoin in preparing an anti-rheumatoid arthritis drug.

[0008] Based on the same inventive concept, the present invention provides a medicine for treating rheumatoid arthritis, wherein the active ingredient of the medicine includes nitrofurantoin.

[0009] Based on the same inventive concept, the present invention provides the use of nitrofurantoin in preparing a drug for inhibiting the proliferation of synovial lining cells.

[0010] Based on the same inventive concept, the present invention also provides the use of nitrofurantoin in preparing a drug for inhibiting osteoporosis.

[0011] Based on the same inventive concept, the present invention also provides the use of nitrofurantoin in preparing a drug for inhibiting bone loss.

[0012] One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:

[0013] 1. The invention discloses an application of nitrofurantoin in the preparation of an anti-rheumatoid arthritis drug. The application applies nitrofurantoin, which is originally an antibacterial drug, to the treatment of rheumatoid arthritis, enriches the types of drugs for the treatment of rheumatoid arthritis, and is expected to provide a new path for the treatment of rheumatoid arthritis.

[0014] 2. The use of nitrofurantoin of the present invention in the preparation of anti-rheumatoid arthritis drugs, nitrofurantoin can significantly improve the symptoms of rheumatoid arthritis in mice, significantly reduce the proliferation of synovial lining cells, and can also significantly inhibit osteoporosis and bone loss caused by rheumatoid arthritis, and significantly reduce the expression of inflammatory factors (IL-1β, IL-6, IL-17, IL-23), while promoting the expression of anti-inflammatory cytokines (IL-10), therefore, nitrofurantoin can be used for the treatment of rheumatoid arthritis. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0016] Figure 1 This is a graph showing the therapeutic effect of nitrofurantoin on rheumatoid arthritis.

[0017] Figure 2 The effect of nitrofurantoin on different inflammatory factors. DETAILED DESCRIPTION

[0018] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.

[0019] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.

[0020] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.

[0021] The overall idea of ​​the present invention is as follows:

[0022] At present, there is a lack of therapeutic drugs for rheumatoid arthritis. Therefore, the development of new target drugs for rheumatoid arthritis is of great scientific and practical significance.

[0023] Nitrofurantoin is an antibacterial drug with a broad spectrum of antibacterial activity. It can be used clinically to treat urinary tract infections caused by sensitive bacteria, and its clinical effectiveness and safety have been clinically confirmed. At present, there are no reports on the use of nitrofurantoin in the treatment of rheumatoid arthritis.

[0024] The inventors have found through a large number of experiments that nitrofurantoin can significantly improve the symptoms of rheumatoid arthritis in mice, including: significantly reducing the proliferation of synovial lining cells, significantly inhibiting osteoporosis and bone loss caused by rheumatoid arthritis, significantly reducing the expression of inflammatory factors (IL-1β, IL-6, IL-17, IL-23), and promoting the expression of anti-inflammatory cytokines (IL-10). Based on this, the present invention proposes to apply nitrofurantoin, which was originally an antibacterial drug, to the treatment of rheumatoid arthritis. It enriches the types of drugs for the treatment of rheumatoid arthritis and is expected to provide a new path for the treatment of rheumatoid arthritis.

[0025] The application of nitrofurantoin in the preparation of anti-rheumatoid arthritis drugs will be described in detail below in combination with examples and experimental data.

[0026] Example 1

[0027] This example conducts an animal model test of nitrofurantoin for treating rheumatoid arthritis, comprising the following steps:

[0028] (1) Animal information: The animals were obtained from Hunan Slake Jingda Experimental Animal Co., Ltd. C57 mice, 20 females, 4-6 weeks old, raised under specific pathogen free (SPF) conditions. The breeding environment was 22-26°C, relative humidity 50%-60%, artificial light on and off for 12 hours each. Adaptive breeding was carried out for 7 days.

[0029] (2) After the adaptive feeding, the mice were randomly divided into a blank control group (n=5) and a rheumatoid arthritis model group (n=15). The blank control group was fed normally without any operation; the rheumatoid arthritis model group (n=15) was treated with a common modeling method for rheumatoid arthritis, i.e., type II collagen was fully mixed with Freund's complete adjuvant to prepare a 2 mg / mL emulsion, which was injected into the left and right foot pads at a dose of 50 uL / mouse, and then boosted with immunization one week later.

[0030] (3) Group intervention. After modeling, the rheumatoid arthritis model group (n = 15) was randomly divided into a model group (n = 5), a nitrofurantoin group (n = 5), and a baricitinib group (n = 5); the model group: normal feeding, no operation. Nitrofurantoin group: nitrofurantoin was injected into the tail vein, the drug amount was 2 mg / kg, the drug concentration was 0.4 mg / mL, the injection volume was 0.1 mL / mouse, once every 2 days, and the intervention lasted for 40 days. Baricitinib group: baricitinib was injected into the tail vein, the drug amount was 2 mg / kg, the drug concentration was 0.4 mg / mL, the injection volume was 0.1 mL / mouse, once every 2 days, and the intervention lasted for 40 days. During the intervention, body weight and arthritis scoring test were performed every day.

[0031] (4) Sampling. After the intervention, the mice were anesthetized with 1% sodium pentobarbital, and blood and hind paws were collected. If the animal was not dead, 100 mg / kg sodium pentobarbital was used to anesthetize the animal until it had no heartbeat and no breathing, and the animal was confirmed dead.

[0032] (5) Micro-CT test: Instrument model: Skyscan 1276Burker

[0033] Fixation and preservation of specimens: First, place the prepared specimens in a 4% paraformaldehyde solution for 24-48 hours; then, take out the specimens and rinse them three times with phosphate buffer; finally, place the specimens in a 75% alcohol solution for storage before sending them for Micro-CT scanning.

[0034] (6) H&E staining:

[0035] I. Use sharp knives and scissors when cutting tissues. When cutting tissue blocks, pull the knife backwards from the base to cut the tissue. Place the fixed mouse left paw tissue with the surface to be cut facing down at the bottom of the plastic embedding box, and dehydrate and wax-immerse according to the usual steps.

[0036] II. Sectioning: Before sectioning, the embedded tissue samples are placed in a -20℃ freezer. The sections can be sliced ​​when the tissue reaches a suitable hardness. The thickness of the sections is 3μm. If the thickness is too thick, the sections will not be firm and will be difficult to observe under the microscope. The embedding will leave certain edges on the top and bottom of the tissue, which is conducive to continuous sectioning and can prevent tissue shrinkage when the sections are unfolded.

[0037] III. Spread and bake the slices: Spread the slices in a water bath, pick up the slices, and carefully attach the slices to the slide. When attaching the slices, keep your hands steady and stretch your hands downward. Then put the slices into the slide spreader, pay attention to make sure there are no bubbles in the slices, stick them flat and tightly, and bake them in time.

[0038] IV. H&E staining: 1) Dewax tissue sections routinely to water; 2) Wash with water for 1-2 minutes; 3) Stain with hematoxylin for 3-6 minutes; 4) Wash with running water to remove hematoxylin for 1-2 minutes; 5) 1% hydrochloric acid alcohol for 1-3 seconds; 6) Wash with water for 1-2 seconds; 7) Blueing solution for 5-10 seconds; 8) Rinse with running water for 15-30 seconds; 9) Stain with 0.5% eosin solution for 2-3 minutes; 10) Wash with distilled water for 1-2 seconds; 11) 80% ethanol for 15-30 seconds; 12) 95% ethanol for 15-30 seconds; 13) Anhydrous ethanol for 1-2 seconds; 14) Xylene (I) for 2-3 seconds; 15) Xylene (II) for 2-3 seconds; 16) Seal with neutral gum.

[0039] V. Image acquisition: Take pictures through a microscope and use the Leica Application Suite imaging system to capture relevant parts of the sample.

[0040] (7) Serum inflammatory factor test:

[0041] a. Dilution of standard: prepare 6 small test tubes, number them in sequence, add 110uL of standard diluent to each small test tube, then take 110uL of the original concentration standard and add it to a numbered test tube, mix thoroughly; then take 110uL from the test tube and add it to the second test tube, mix thoroughly; then take 110uL from the test tube and add it to the third test tube, mix thoroughly; then take 110uL from the test tube and add it to the fourth test tube, mix thoroughly; then take 110uL from the test tube and add it to the fifth test tube, mix thoroughly; then take 110uL from the test tube and discard it. The sixth test tube is used as standard No. 0.

[0042] b. Sample addition: Set up standard wells, blank wells, and sample wells on the enzyme-labeled plate. Add 50uL of standards of different concentrations to the standard wells in turn; first add 40uL of sample to the sample wells, and then add 10uL of biotin-labeled antibody.

[0043] c. Add enzyme and incubate: Add 50uL of enzyme-labeled reagent to each well except the blank well, seal the plate with a sealing film and incubate in a 37°C incubator for 30 minutes.

[0044] d. Washing: Dilute the concentrated washing solution 30 times with distilled water, carefully peel off the sealing film, discard the liquid in the wells, spin dry, fill each well with washing solution, let it stand for 30 seconds and then discard, repeat this 5 times and pat dry.

[0045] e. Color development: First add 50 uL of color developer A to each well, then add 50 uL of color developer B, gently shake to mix, and develop the color at 37℃ in the dark for 10 minutes.

[0046] f. Termination and determination: Add 50uL of stop solution to each well to terminate the reaction; adjust the blank well to zero, and measure the absorbance (OD value) of each well in sequence at a wavelength of 450nm. The determination should be carried out within 15 minutes after adding the stop solution.

[0047] The test results are as follows Figure 1 shown.

[0048] After the experiment, three groups of data were randomly selected for statistical analysis. The results are as follows: Figure 1 A shows the establishment of a rheumatoid arthritis mouse model and the schematic diagram of drug intervention, as well as the scores of rheumatoid arthritis and palm thickness of mice in different groups. As can be seen from the figure, nitrofurantoin can significantly improve the symptoms of rheumatoid arthritis, and its efficacy is comparable to that of the commercial drug baricitinib. Figure 1 B shows the Micro-CT images of the paws of mice in different groups and the results of related bone analysis parameters. As can be seen from the figure, the rheumatoid arthritis group has typical characteristics of bone loss, and the number of trabeculae (Tb, N) and bone mineral density (BMD) are reduced, indicating that rheumatoid arthritis mice have more serious osteoporosis and bone loss; while the CT images, Tb, N and BMD values ​​of the drug intervention groups (i.e., nitrofurantoin group and baricitinib group) have significantly improved or increased compared with the rheumatoid arthritis group, indicating that nitrofurantoin has a good therapeutic effect. Figure 1 C shows the H&E staining images of the joints of mice in different groups. It can be seen from the figure that the rheumatoid arthritis group (i.e., RA model group) produced obvious synovial lining cells hyperplasia; while the hyperplasia in the drug intervention group was significantly inhibited. Figure 2The concentrations of typical inflammatory factors or anti-inflammatory cytokines in the serum of mice in different groups were displayed. The results showed that the drug group significantly reduced the expression of inflammatory factors (IL-1β, IL-6, IL-17, IL-23) and promoted the expression of anti-inflammatory cytokines (IL-10).

[0049] The above results all indicate that nitrofurantoin can effectively relieve the symptoms of rheumatoid arthritis, inhibit the expression of multiple inflammatory factors, and has a good therapeutic effect on rheumatoid arthritis.

[0050] Finally, it should be noted that the terms "comprises," "includes," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements that are inherent to such process, method, article, or apparatus.

[0051] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0052] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. The use of nitrofurantoin as the sole active ingredient in the preparation of anti-rheumatoid arthritis drugs.

2. The use according to claim 1, characterized in that: The drug inhibits the proliferation of synovial lining cells.